- 0 Comments
- 1987 reads
Innocoll, Inc (Athlone, Ireland) announces that the US Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to conduct a Phase 2 Study for CollaRx™ gentamicin as a topical antibiotic treatment for mildly infected diabetic foot ulcers.
CollaRx gentamicin is a biodegradable and fully resorbable gentamicin collagen sponge formulated and manufactured using Innocoll’s proprietary CollaRx technology. Upon application to wounds, the product releases gentamicin—a concentration-dependent aminoglycoside antibiotic used for local action.
Visit http://www.innocoll.com for more information.
RecoverCare and Sten-Barr Finalize Merger
RecoverCare (Plymouth Meeting, Pa) and Sten-Barr Medical (Tampa, Fla) have signed an agreement that will combine the companies. Both organizations offer therapeutic support surfaces, specialty beds, and bariatric equipment to hospitals, nursing homes, and home care patients. The deal was finalized in January 2007.
The merger will result in better service to both companies and existing customers. This growth initiative is a bold step to enhance the national leaders in specialty mattresses and beds.
Visit http://www.recovercare.com or http://www.stenbarr.com for more information.
Bayer Licenses Biodrug Delivery Technology for Wound Care
DelSiTech (Turku, Finland) signed a license agreement with Bayer Innovation, a subsidiary of Germany’s Bayer group, in a deal that could lead to the creation of a new generation of wound care products.
Bayer wants to use DelSiTech’s novel silica-based biodrug delivery technology in the wound care setting. Under the terms of the agreement, Bayer Innovation gets exclusive rights to use DelSiTech’s technology in wound application. In return, DelSiTech receives a signing fee, milestone payments, and royalties covering future sales of products using the technology.
With wound care being a critically important area with unmet medical need, Bayer and DelSiTech will undoubtedly find new applications for technology.
Visit http://www.delsitech.com/eng/news for more information.